Endothelial progenitor cell function • MicroRNA-26a • EphA2 • p38 MAPK/VEGF pathway Abstract Background: Dysfunction of circulating endothelial progenitor cells (EPCs) is associated with the onset of cardiovascular disorders. Circulating microRNAs (miRNAs) have been recognized as novel biomarkers and potential therapeutic targets. Here, we examined the role of miR-26a overexpression in atherosclerosis and explored the underlying mechanisms. Methods: EPCs were obtained from patients with atherosclerosis and healthy controls. Bone marrow (BM)-derived EPCs were exposed to hypoxia to mimic the atherosclerotic environment and miR-26a, EphA2 and p38 MAPK levels were measured by qRT-PCR and western blotting, and VEGF levels were determined by enzyme linked immunosorbent assay. Cell viability was assessed using the MTT assay, and luciferase activity assays confirmed EphA2 as a target of miR-26a. Results: MiR26a was overexpressed in patients with atherosclerosis and associated with EPC dysfunction. EphA2 was identified as a direct target of miR-26a. Overexpression of miR-26a downregulated EphA2 and impaired EPC function, whereas knockdown of miR-26a upregulated EphA2 and reversed hypoxia-induced EPC dysfunction. MiR-26a overexpression or knockdown modulated the activity of p38 MAPK and the levels of VEGF in EPCs. Conclusions: The role of miR-26a in atherosclerosis is mediated by its target EphA2 via a mechanism involving the p38 MAPK/ VEGF pathway.
Introduction
Atherosclerosis is one of the primary causes of cardiovascular disease and an important cause of mortality worldwide [1] . The formation of lipid rich plaques within the arterial wall, which is the hallmark of this disease, occurs via an inflammatory process resulting from the interaction between lipoproteins, monocyte-derived macrophages, T cells and the components of the arterial wall [2] . Two processes associated with plaque, namely hypoxia and inflammation, induce the expression of vascular endothelial growth factor (VEGF) to promote angiogenesis, which is the formation of new blood vessels from pre-existing ones [3, 4] . Endothelial progenitor cells (EPCs) are primitive bone marrow (BM) cells that possess the capacity to mature into endothelial cells (ECs) and play a role in neovascularization and vascular remodeling through the repair of endothelial lesions [5] . Because circulating EPCs can home to sites of neovascularization and differentiate into endothelial cells, they have been studied extensively for their application in cell therapy, and their transplantation has been used as a new strategy for the treatment of ischemic diseases [6] . However, the efficiency of EPC transplantation is limited by the functional integrity of EPCs, which is impaired in certain disease states. The development of strategies to improve EPC function is an area of active research.
MicroRNAs (miRNAs) are a class of small (22-nucleotide) non-coding RNAs than regulate gene expression by binding to the 3′ untranslated region (3′-UTR) of their target mRNAs, modulating mRNA stability and/or translation [7] . MiRNAs are differentially expressed in various cells and tissues and they regulate the expression of a wide variety of target genes [8] ; therefore, they have been studied extensively as biomarkers of disease and therapeutic targets [9, 10] . MiRNAs have been primarily investigated for their role in cancer, although their deregulation has been implicated in the pathogenesis of many human diseases. MiRNAs are highly expressed in the cardiovascular system and they have been implicated in the development of cardiovascular diseases including atherosclerosis [11, 12] . The role of miRNAs in the regulation of angiogenesis, endothelial cell function and vascular inflammation was described previously [13] . MiR-26a, an miRNA possiblely plays a dual role in tumorigenicity, functioning either as a tumor suppressor or promoter [14] . Studies have indicated cell type-specific effects of miR-26a on neovascularization. While miR-26a promotes tumor angiogenesis in glioma [15] , miR-26a expression significantly suppressed in vivo tumor-associated angiogenesis in HCC [14, 16] . Interestingly, ectopic expression of miR-26a markedly induced endothelial cell cycle arrest and inhibited ECs migration, sprouting angiogenesis, and network tube formation in matrigel in vitro and in vivo [17] . The expression profile and functions of miR-26a in EPCs remain to be defined.
Ephrin receptor A2 (EphA2) belongs to a large family of protein tyrosine kinase receptors, the Eph family of receptors, which is divided into two subclasses depending on their ligands [18] . EphA2 has been studied extensively because of its overexpression in several human cancers including melanoma, breast cancer, prostate cancer, non-small cell lung cancer and colon cancer [19] [20] [21] [22] [23] . EphA2 activation plays a role in VEGF-induced endothelial cell migration [24] , and EphA2 overexpression is associated with markers of angiogenesis such as high microvessel density and invasion, and increased matrix metalloprotease expression [25] . Eph receptors are involved in chronic inflammatory diseases and immune responses, and EphA2 plays a role in inflammation and cardiovascular diseases [26] .
The extracellular-signal-regulated kinase (ERK)/p38 mitogen activated protein kinase (MAPK) pathway is involved in endothelial cell proliferation and migration in response to activation by several growth factors. VEGF plays an important role in vascular permeability and angiogenesis by promoting the migration, proliferation and elongation of endothelial cells [27] , and VEGF is a known regulator of p38 MAPK activity in relation to several cellular functions [28] .
In the present study, we investigated the role of miR-26a upregulation in EPCs and its correlation with atherosclerosis. EphA2 was identified as a direct target of miR-26a and shown to mediate the effects of miR-26a on EPC vasculogenesis, proliferation, and migration. 
Cellular Physiology and Biochemistry
Further investigation showed that the effect of the miR-26a/EphA2 axis on EPC function is mediated by a mechanism involving the p38 MAPK/VEGF pathway.
Materials and Methods

Patients and sample collection
Patients were recruited from Shanghai Tenth People's Hospital (Shanghai, China) and blood samples were collected from untreated patients. The control group consisted of healthy volunteers. All protocols were approved by the Research Ethics Committee of our institution. Informed consent was obtained from all patients before sample collection. EPCs were isolated from the blood of patients with atherosclerosis and controls using a Becton-Dickinson FACS Aria flow cytometer (BD Biosciences, San Jose, CA, USA).
Cell culture and reagents
Eight-week-old male Lewis rats were purchased from Shanghai Slac Laboratory Animal Co. Ltd. (Shanghai, China).
For hypoxic conditions, mice were fed a high-cholesterol diet (TD88051 [Harlan Teklad, Madison, WI]: 4 kcal/g, 15.8% fat, and 1.25% cholesterol) with an F IO2 of 5% delivered 60 times per hour.
For normal controls, mice were fed a regular diet (3.3 Cal/g, 4% fat) with intermittent air (IA) at the identical flow rate.
Mice were killed by injection of an overdose of sodium pentobarbital. The bone marrow cavities were flushed twice with 0.01 mol/l pre-cooled phosphate-buffered saline (PBS). The cell pellets were washed twice with PBS and resuspended in M199 medium (Gibco BRL, Grand Island, NY, USA).
Bone marrow mononuclear cells (BMMCs) were obtained from the cell suspension by centrifugation through a Ficoll-isopaque density gradient. To obtain EPCs, the BMMCs were allowed to adhere to 6-well plates in M199 medium for 1 h at 37°C in a 5% CO2 incubator. Non-adherent cells were collected and cultured in M199 medium supplemented with 10% fetal calf serum, 10 ng/ml VEGF and 2 ng/ml basic fibroblast growth factor at 37°C in a 5% CO2 incubator. After 3 h, non-adherent cells were removed and adherent cells were cultured for 7 days.
Cell proliferation assay
Cell viability was evaluated by the MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay. Cells were seeded in triplicate in 96-well plates at a density of 1×10 4 cells/well and maintained in a humidified atmosphere of 5% CO2 in air at 37°C. Cells were treated with 0.125 mg/mL MTT (Invitrogen, Carlsbad, CA, USA) for 3 h. The medium was then removed and DMSO (100 μl/well) was used to dissolve the insoluble purple formazan product. OD 490 in each well was determined by a microplate reader, which reflected the number of viable cells. Assays were performed in triplicate wells. Data were presented as means and SD from three independent experiments.
Luciferase reporter assay
A fragment from the 3′ UTR of EphA2 containing the putative miR-26a binding site was cloned into the pGL3-Basic vector (Promega, Madison, Wisconsin, USA). The primers for the EphA2 3′-UTR were as follows:
EphA2-UTR-F: CCGctcgagCCTGGAGCCCCATCGGCCAAGAATA EphA2-UTR-R: TTCCTTTTgcggccgcAGAGCAGAAATAAGTCATTTTC Mutant (Mut) constructs were generated by mutating the seed region of the miR-26a binding site. MiR-26a expressing or control cells were cultured in 24-well plates, and transfected with 100 ng luciferase reporter plasmid and 5 ng. pRL-TK vector expressing Renilla luciferase (Promega) using Lipofectamine 2000 (Invitrogen). After 48 h, cells were harvested, lysed and luciferase activity was measured using the DualLuciferase Reporter Assay System (Promega) according to the manufacturer's protocol. Renilla luciferase was used for normalization. All assays were performed in triplicate and repeated at least three times.
Real-time quantitative RT-PCR
To quantify the expression level of mature miR-26a, the isolated RNA was reverse transcribed and amplified by a two-step quantitative RT-PCR method using the Hairpin-it TM miRNA qPCR Quantitation Kit (Gene-pharma, Shanghai, China) according to the manufacturer's protocol. The primers used were as follows: miR-26a-F: 5′-CTGTCAACGATACGCTAC-3′; miR-26a-R: 5′-GTAATCCAGGATAGGCTG-3′ U6-F: 5′-CTTCGGCAGCACATATAC-3′; U6-R: 5′-GAACGCTTCACGAATTTGC-3′ miR-26a for RT: 5′-GCTGTCAACGATACGCTACCTAACGGCATGACAGTGTCagccta-3′; U6 for RT: 5′-GAACGCTTCACGAATTTGC-3′
Real-time PCR for EphA2 was performed using the ABI 7300System (Bio-Rad, CA) with the QuantiTect SYBR Green PCR mixture (Invitrogen). The primers used were as follows: EphA2-F: 5′-CACTTACCGCAAGAAGGGAGA-3′; EphA2-R: 5′-ACAGCCACGCCGCCAATCA-3′.
miRNA transfection MiR-26a was overexpressed or silenced in EPCs using recombinant lentivirus vectors containing premiR-26a, negative control precursor miRNA, anti-miRNA against miR-26a or negative control for the antimiRNA. The vectors together with packaging vectors were transfected into EPCs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and the transfection results were verified by qRT-PCR.
Enzyme linked immunosorbent assay (ELISA)
The levels of VEGF were determined by ELISA using a commercially available kit (R&D Systems, Minneapolis MN; BD Biosciences, San Diego, CA) according to the manufacturer's instructions. All assays were performed in duplicate.
Western blot analysis
For western blot analysis, EPCs were lysed in lysis buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin, and 1 mM PMSF and centrifuged at 12,000 rpm for 5 min. Aliquots containing 20 µg of protein were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Milipore). After blocking in 5% nonfat milk in PBS, blots were incubated with primary antibodies overnight at 4°C followed by incubation with horseradish peroxydase conjugated secondary goat anti-rabbit antibodies (1:4000 dilution, PerkinElmer, USA). Primary antibodies used and their dilutions were as follows: anti-EphA2 (1:500, Santa Cruz Biotechnology, Santa Cruz, CA), anti-phospho-p38 MAPK and anti p38 MAPK (1:500, Cell Signaling Technology, Beverly, MA). GAPDH was detected as the loading control.
EPC tube formation and Transwell cell migration assays
In vitro tube formation was assessed as described previously [29] . Briefly, basement membrane extracts were plated in 96-well plates at 37°C to form a reconstituted basement membrane. EPCs were collected by trypsin/EDTA and 1×10 4 cells in 100 ml medium were seeded on Matrigel and incubated at 37°C for 6 h. Tube formation was examined under an inverted light microscope and measured by analyzing five representative fields and calculating the total tube length in each group. All data are the results of three independent experiments performed in triplicate. The results were expressed as relative to the control group.
For Transwell cell migration assays, 600 µl medium containing 10% fetal bovine serum (FBS) was added to the lower chamber of Costar Transwell Polycarbonate Permeable Supports (Corning, NY, USA). EPCs (5×10 4 ) in 100 µl medium were added to the upper chamber and incubated at 37°C for 3 h, after which the cell suspensions were removed from the upper chamber and membranes were fixed in 4% paraformaldehyde. Migrated cells were stained with Hoechst 33342 reagent for 30 min and counted in five representative fields under a fluorescent microscope.
Results
MiR-26a is upregulated in endothelial progenitor cells and associated with atherosclerosis
EPCs were separated from the blood of patients with atherosclerosis and healthy controls and analyzed by phase contrast microscopy, which showed a monolayer of cobblestoneappearing cells typical of late EPCs (Fig. 1A) . Quantification of miR-26a expression by RTqPCR showed significantly higher levels in EPCs of atherosclerosis patients than in those of the control group (p < 0.01) (Fig. 1B) . Both EPCs were negative for the hematopoietic marker CD45 yet the CD34 precursor gene. They also expressed endothelial markers KDR (Fig. 1C) .
Hypoxia upregulates miR-26a in EPCs in correlation with decreased cell viability, tube formation ability and migration
The expression of miR-26a was examined in EPCs under conditions of hypoxia to mimic the atherosclerotic environment. The results of qRT-PCR showed significantly increased levels of miR-26a in EPCs exposed to hypoxia than in control EPCs (p < 0.05) (Fig. 2A) . Assessment of cell viability using the WST-1 assay showed a significant reduction in the proliferation of EPCs up to day 9 under conditions of hypoxia compared to the untreated controls (p < 0.05) (Fig. 2B) . To examine the effect of hypoxia on the angiogenic capacity of EPCs, tube formation and EPC migration were assessed under conditions of hypoxia. The results showed that hypoxia inhibited tube formation by approximately 65% and migration by approximately 45% in EPCs (p < 0.05) (Fig. 2C) . 
Cellular Physiology and Biochemistry
Mir-26a downregulates EphA2 and impairs EPC function
Target genes of miR-26a were identified using the online miRNA target prediction programs miRanda (http://www.microrna.org), TargetScan (http://www. targetscan.org) and PicTar (http://www.pictar.bio.nyu.edu). Approximately 100 targets of miR-26a were predicted from these programs. EphA2 was of particular interest and was thus explored as a potential target mediating the effect of miR-26a in EPCs.
Overexpression of miR-26a was confirmed by qRT-PCR and its effect on the expression of EphA2 was measured by RT-PCR and western blotting. The results showed that ectopic expression of miR-26a significantly downregulated the expression of EphA2 in EPCs at the mRNA (more than 5-fold downregulation) and protein levels (Fig. 3A) . Overexpression of miR-26a significantly inhibited cell proliferation, tube formation and the migration ability of EPCs (p < 0.05 all) (Fig. 3B and C) .
Mir-26a knockdown upregulates EphA2 and reverses hypoxia-induced EPC dysfunction
Knockdown of miR-26a by anti-miR transfection significantly upregulated the expression of EphA2 at the mRNA (approximately 3.2-fold upregulation) and protein levels in EPCs, as determined by qRT-PCR and western blotting (Fig. 4A) . Furthermore, knockdown of miR-26a and the consequent upregulation of EphA2 reversed the effect of hypoxia on impairing EPC function, as determined by the restoration of tube formation and migration abilities (Fig. 4B) . Figure 5A shows the sequence alignment of the miR26a seed region and the predicted miR-26a binding site in the 3′-UTR of wild-type (WT) EphA2, as well as a mutant (MUT) 3′-UTR or EphA2 generated by site-directed mutagenesis. The WT or MUT 3′-UTR of EphA2 containing the putative miR-26a binding site was cloned downstream of the luciferase reporter gene. Luciferase reporter assays showed that miR-26a significantly decreased the luciferase activity of the EphA2 WT 3′ UTR but not that of the mutant, indicating that EphA2 is a direct target of miR-26a (Fig. 5B) .
Cellular Physiology and Biochemistry
EphA2 is a direct target of miR-26a
The effect of miR-26a/EphA2 on EPC function is mediated by the p38 MAPK/VEGF pathway
To explore the mechanism by which miR-26a modulates EPC function, the expression of VEGF and the activation status of p38MAPK were examined in EPCs after overexpression or antagomir mediated knockdown of miR26a. The results showed that miR-26a overexpression significantly reduced the levels of phospho-p38 MAPK and downregulated VEGF expression ( Fig. 6A and B) , whereas anti-miR-26a had the opposite effect ( Fig. 6C and D) (p < 0.05 all) . 
Discussion
In the present study, we investigated the effect of miR-26a overexpression on EPC function and explored the underlying mechanisms. Hypoxia-induced EPC dysfunction, as determined by decreased viability and impaired tube formation and migration ability, was accompanied by miR-26a upregulation. Furthermore, ectopic expression of miR-26a mimicked the effects of hypoxia on EPC function. We identified the EphA2 receptor as a direct target of miR-26a and showed that the effect of miR-26a on the impairment of EPC function is mediated by its target EphA2 via a mechanism involving the p38 MAPK/VEGF pathway.
MiRNA dysregulation plays important roles in different phases of atherosclerosis development, from plaque formation to endothelial cell function and angiogenesis [30] . Several miRNAs have been identified that are up-or down-regulated in endothelial dysfunction leading to the development of atherosclerosis. Among them, miR-126 is one of the most abundant miRNAs in ECs and plays an important role in angiogenesis and vascular integrity [31] , in addition to having a protective effect against atherosclerosis in mice by targeting RGS16 [32] . MiR-181b and miR10a are involved in atherosclerosis development by modulating the activity of the NF-κB pathway [33, 34] . Several miRNAs have been implicated in the regulation of angiogenesis: miR-126, miR-130a, miR-210 and the miR23-miR27-miR24 cluster promote angiogenic activity, whereas miR-221/miR222, miR-92a and miR217 inhibit angiogenesis in endothelial cells [35] [36] [37] [38] [39] [40] [41] . Overexpression of miR-34 impairs EPC angiogenesis in parallel with the downregulation of SIRT1 [42] . In the present study, we showed that miR-26a is upregulated and plays a role in EPC dysfunction in atherosclerosis.
MiR26a has been shown to function in both promoting and inhibiting cell proliferation in different cell types. MiR-26a inhibits osteogenic differentiation of adipose tissue-derived stem cells [43] and promotes tumor formation in glioma [44] . MiR-26a promotes vascular smooth muscle cell proliferation by targeting TGF-β/BMP pathway signaling [45] . On the other hand, ectopic expression of miR-26a induced cell cycle arrest in endothelial cells and inhibited EC migration, angiogenesis and tube formation [17] . In hepatocellular carcinoma (HCC), miR-26a was shown to promote cell cycle arrest in vitro and adeno-associated virusmediated miR-26a delivery suppressed cell proliferation and promoted apoptosis in vivo [46] . Consistently, miR-26a attenuated cell proliferation and impaired cell cycle progression by targeting the Polycomb complex protein EZH2 in association with lymphomagenesis [47] . MiR-26a was shown to play a role in angiogenesis in HCC through its effect on the PI3K-C2α/ Akt/VEGF signaling pathway [16] . Ectopic expression of miR-26a downregulated VEGFA and impaired migration and tube formation in human umbilical vein endothelial cells. These findings are consistent with the results of the present study showing that ectopic expression of miR-26a inhibited VEGF expression and suppressed the angiogenic potential of EPCs, whereas anti-miR-26a restored VEGF levels and angiogenic activity.
We identified EphA2 as a direct target of miR-26a and elucidated a potential mechanism by which miR-26a affects EPC function by modulating VEGF expression and the activity of the p38 MAPK pathway through its target EphA2. Ephs and ephrins were originally identified in a tumorigenesis model, and research on Eph-ephrin interactions have been predominantly focused on their role in carcinogenesis. However, later studies showed their involvement in a variety of chronic diseases [26] . EphA2 expression in endothelial cells has been implicated in inflammatory processes associated with atherosclerosis, such as proinflammatory gene expression [48] and endothelial barrier dysfunction [49, 50] , as well as in angiogenesis [51, 52] . Enhanced expression of EphA2 and its ligand ephrinA1 in activated endothelial cells suggests that they play a role as mediators of atherogenic inflammation [26] . Furthermore, increased endothelial EphA2 signaling during endothelial cell activation promotes the expression of proinflammatory genes, thus inducing an inflammatory response. The role of EphA2 in angiogenesis has been well characterized, in particular in models of tumorigenesis, ischemia-reperfusion injury and hypoxia [52] [53] [54] [55] [56] . These data support the findings of the present study by illustrating the role of EphA2 in inflammation and vascular remodeling and the correlation between EphA2 signaling and atherosclerosis.
In the present study, we showed that miR-26a overexpression inhibited the activation of p38 MAPK and downregulated VEGF expression, whereas silencing of miR-26a had the opposite effects. VEGF is one of the most potent angiogenic factors and it increases vascular permeability and endothelial cell survival in vessels [57, 58] , and activation of p38 MAPK plays a role in the modulation of VEGF levels. These findings together with the results of the present study confirming the effect of miR-26a on the downregulation of VEGF suggest a potential mechanism underlying EPC dysfunction involving miR-26a and the p38 MAPK/ VEGF pathway. Further studies aimed at elucidating the precise mechanism by which miR26a and its target EphA2 modulate EPC function are warranted.
In conclusion, in the present study we showed that miR-26a is upregulated in EPCs in atherosclerosis and its ectopic expression induces EPC dysfunction, mimicking the effects of hypoxia. We identified EphA2 as a direct target of miR-26a and showed that miR-26a overexpression or silencing modulated EphA2 levels concomitant with alterations in the angiogenic and proliferative abilities of EPCs, suggesting that the effects of miR-26a on the function of EPCs are mediated by EphA2. Furthermore, miR-26a overexpression or silencing modulated the activity of p38 MAPK and the levels of VEGF. Taken together, our findings suggest that the role of miR-26a in atherosclerosis is mediated by a mechanism that involves its target EphA2 and the p38 MAPK pathway, providing potential new biomarkers and therapeutic targets for patients with atherosclerosis.
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